Fibrocell Science (FCSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -34,453 | -16,802 | -15,281 | -8,525 | -25,650 |
| Depreciation Amortization | 767 | 554 | 346 | 140 | 883 |
| Accounts receivable | 9 | 9 | 2 | 1 | 12 |
| Accounts payable and accrued liabilities | 9,605 | 1,332 | 723 | 1,229 | -1,355 |
| Other Working Capital | 10,420 | 2,463 | 2,044 | 2,244 | -17 |
| Other Operating Activity | -10,454 | -4,036 | 1,379 | 673 | 3,831 |
| Operating Cash Flow | $-24,106 | $-16,480 | $-10,787 | $-4,238 | $-22,296 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -245 | -208 | -111 | -108 | -242 |
| Investing Cash Flow | $-245 | $-208 | $-111 | $-108 | $-242 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -3 | -3 | -2 | N/A | N/A |
| Common Stock Issued | 16,127 | 16,127 | 255 | 152 | N/A |
| Financing Cash Flow | $16,124 | $16,124 | $253 | $152 | $N/A |
| Beginning Cash Position | 37,495 | 37,495 | 37,495 | 37,495 | 60,033 |
| End Cash Position | 29,268 | 36,931 | 26,850 | 33,301 | 37,495 |
| Net Cash Flow | $-8,227 | $-564 | $-10,645 | $-4,194 | $-22,538 |
| Free Cash Flow | |||||
| Operating Cash Flow | -24,106 | -16,480 | -10,787 | -4,238 | -22,296 |
| Capital Expenditure | -271 | -208 | -111 | -108 | -242 |
| Free Cash Flow | -24,377 | -16,688 | -10,898 | -4,346 | -22,538 |